Personalized medicine in pancreatic cancer: the revolution has begun

被引：1

作者：

Marechal, Raphael ^{[1
,2
,3
]}

Puleo, Francesco ^{[1
,2
,3
]}

Demols, Anne ^{[1
,2
]}

Verset, Gontran ^{[1
,2
]}

Van Laethem, Jean-Luc ^{[1
,2
]}

机构：

[1] Univ Libre Bruxelles, Erasme Hosp, Dept Gastroenterol, B-1070 Brussels, Belgium

[2] Univ Libre Bruxelles, Erasme Hosp, Gastrointestinal Canc Unit, B-1070 Brussels, Belgium

[3] Univ Libre Bruxelles, Erasme Hosp, Lab Expt Gastroenterol, B-1070 Brussels, Belgium

来源：

PERSONALIZED MEDICINE | 2015年 / 12卷 / 05期

关键词：

expression profiling; genomic; neoadjuvant therapy; pancreatic cancer; prognostic and predictive biomarkers; PHASE-III TRIAL; NEEDLE-ASPIRATION BIOPSY; NAB-PACLITAXEL; DUCTAL ADENOCARCINOMA; ADJUVANT GEMCITABINE; CURATIVE RESECTION; SPARC EXPRESSION; PREDICT SURVIVAL; TUMOR DNA; THERAPY;

D O I：

10.2217/pme.15.15

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pancreatic ductal adenocarcinoma carries a dismal prognosis. Both chemotherapy and targeted therapies have been disappointing when administered to unselected populations. Recently, progress has been made in our understanding of the genomic landscape of this cancer which displays remarkable heterogeneity suggesting a reorientation of management and research strategies based on molecular characterization and adapted personalized therapy. Resectable disease offers new opportunities for translational research through functional imaging response evaluation and tumor tissue acquisition before and after neoadjuvant therapy. There is urgent need for clinical trials based on molecular profiling in pancreatic ductal adenocarcinoma. In this review we discuss opportunities and limitations of these new strategies, underlining the importance of tissue acquisition and integration of molecular biomarkers in future molecularly driven clinical trials.

引用

页码：515 / 523

页数：9

共 50 条

[1] Cancer: the revolution has begun
不详
[J]. LANCET, 2010, 376 (9747): : 1117 - 1117
[2] The Revolution Has Begun
Hyman, Steven E.
Nikolich, Karoly
[J]. TRANSLATIONAL NEUROSCIENCE: TOWARD NEW THERAPIES, 2015, : 247 - 253
[3] The revolution has begun
Coghlan, A
Le Page, M
[J]. NEW SCIENTIST, 2001, 169 (2278) : 4 - 5
[4] Diverse perspectives on the current state of genomic medicine: has the revolution begun?
Dhara M MacDermed
Liliana Uribe-Bruce
[J]. Genome Medicine, 3
[5] Diverse perspectives on the current state of genomic medicine: has the revolution begun?
MacDermed, Dhara M.
Uribe-Bruce, Liliana
[J]. GENOME MEDICINE, 2011, 3
[6] The filler revolution has just begun
Dover, JS
[J]. PLASTIC AND RECONSTRUCTIVE SURGERY, 2006, 117 (03) : 38S - 40S
[7] Illumination optimization: The revolution has begun
Cassarly, WJ
Hayford, MJ
[J]. INTERNATIONAL OPTICAL DESIGN CONFERENCE 2002, 2002, 4832 : 258 - 269
[8] Personalized RNA Medicine for Pancreatic Cancer
Gilles, Maud-Emmanuelle
Hao, Liangliang
Huang, Ling
Rupaimoole, Rajesha
Lopez-Casas, Pedro P.
Pulver, Emilia
Jeong, Jong Cheol
Muthuswamy, Senthil K.
Hidalgo, Manuel
Bhatia, Sangeeta N.
Slack, Frank J.
[J]. CLINICAL CANCER RESEARCH, 2018, 24 (07) : 1734 - 1747
[9] The future of academic medicine has begun
Whitcomb, ME
[J]. ACADEMIC MEDICINE, 2004, 79 (04) : 281 - 282
[10] On Russian Farms, the Robotic Revolution Has Begun
Uskova, Olga
[J]. IEEE SPECTRUM, 2021, 58 (09) : 40 - 45

← 1 2 3 4 5 →